benzyl (3-bromophenyl)carbamate | 361337-08-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl (3-bromophenyl)carbamate
• 英文别名: benzyl N-(3-bromophenyl)carbamate
• CAS: 361337-08-8
• 化学式: C₁₄H₁₂BrNO₂
• mdl: MFCD01013390
• 分子量: 306.159
• InChiKey: RKTXDGRJOLJFAG-UHFFFAOYSA-N

物化性质

• 沸点：
  366.1±35.0 °C(Predicted)
• 密度：
  1.487±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  benzyl (3-bromophenyl)carbamate 在 potassium phosphate 、 2’-(dimethylamino)-2-biphenylyl-palladium(II)chloride dinorbornylphosphine complex 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 16.5h， 生成 2-(3'-(((benzyloxy)carbonyl)amino)-[1,1'-biphenyl]-2-yl)acetic acid
  参考文献：
  名称：

  Identification of a novel class of autotaxin inhibitors through cross-screening

  摘要：

  从已知的LPA₁拮抗剂4开始，通过骨架跳跃和基于配体的设计的组合，确定了以7，8和9为代表的三个新系列的自动税林抑制剂。

  DOI：

  10.1039/c5md00081e
• 作为产物：
  描述：

  间溴苯甲酸 、 氯甲酸苄酯 在 sodium azide 、 sodium t-butanolate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 16.0h， 以72%的产率得到benzyl (3-bromophenyl)carbamate
  参考文献：
  名称：

  芳族羧酸的Curtius重排，以得到受保护的苯胺和芳族脲。

  摘要：

  氯甲酸酯或二碳酸二叔丁酯与叠氮化钠与芳族羧酸的反应产生相应的酰基叠氮化物，大概是通过形成叠氮甲酸酯。酰基叠氮化物经历Curtius重排以形成异氰酸酯衍生物，该异氰酸酯衍生物被醇盐或胺捕获而形成芳族氨基甲酸酯或脲。反应条件与各种官能团相容，并允许合成许多含有烷基，卤化物，硝基，酮，醚和硫醚取代基的苯胺衍生物。[反应：看文字]

  DOI：

  10.1021/ol0622920

文献信息

• Azide monoliths as convenient flow reactors for efficient Curtius rearrangement reactions
  作者：Marcus Baumann、Ian R. Baxendale、Steven V. Ley、Nikzad Nikbin、Christopher D. Smith

  DOI：10.1039/b801634h

  日期：——

  The preparation and use of an azide-containing monolithic reactor is described for use in a flow chemistry device and in particular for conducting Curtius rearrangement reactions via acid chloride inputs.

  描述了一种含叠氮化物的整体反应器的制备和使用，该反应器用于流动化学装置中，尤其是用于通过酰氯输入进行库尔修斯重排反应。
• Purinenucleoside derivative modified in 8-position and medical use thereof
  申请人：Tatani Kazuya

  公开号：US20070179115A1

  公开（公告）日：2007-08-02

  The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R A is a hydrogen atom or a hydroxyl group; R 1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R 2 to R 4 , P 1 and Q represents a halogen atom, a cyano group or the like.

  本发明提供了一种用于与血浆尿酸水平异常相关疾病的8-修饰嘌呤核苷衍生物。以下式（I）所代表的一种8-修饰嘌呤核苷衍生物、其前药或药用盐、或其水合物或溶剂化合物，对于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗具有用处。在该式中，n为1或2；RA是氢原子或羟基；R1是氢原子、羟基、硫醇基、氨基或氯原子；环J代表可选地取代的2-萘基，或由以下一般式（II）所代表的基团，其中Y代表单键或连接基团；环Z代表可选地取代的芳基或杂环芳基等；而R2至R4、P1和Q代表卤素原子、氰基或类似物。
• Purine nucleoside derivative modified in 8-position and medical use thereof
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US07795236B2

  公开（公告）日：2010-09-14

  The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

  本发明提供了一种8-修饰嘌呤核苷衍生物，该衍生物对于与血浆尿酸水平异常相关的疾病具有用途。式（I）所表示的8-修饰嘌呤核苷衍生物，其前药或其药学上可接受的盐，或其水合物或溶剂化物，对于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗有用。 在式中，n为1或2；RA为氢原子或羟基；R1为氢原子、羟基、硫醇基、氨基或氯原子；环J代表一个可选择取代的2-萘基团，或由下述通式（II）所表示的团基，其中Y表示单键或连接基；环Z代表一个可选择取代的芳基团或杂环芳基团等；而R2至R4、P1和Q代表卤素原子、氰基或类似物。
• PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF
  申请人：Tatani Kazuya

  公开号：US20100249054A9

  公开（公告）日：2010-09-30

  The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R A is a hydrogen atom or a hydroxyl group; R 1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R 2 to R 4 , P 1 and Q represents a halogen atom, a cyano group or the like.

  本发明提供了一种8-修饰嘌呤核苷衍生物，用于与血浆尿酸水平异常相关的疾病。公式（I）所表示的8-修饰嘌呤核苷衍生物，其前体药物或其药学上可接受的盐，或其水合物或溶剂化物，可用于痛风、高尿酸血症、泌尿系结石、高尿酸性肾病等的预防或治疗。在公式中，n为1或2；RA是氢原子或羟基；R1是氢原子、羟基、硫醇基、氨基或氯原子；环J表示可选取的2-萘基团，或由以下通式（II）所表示的基团，其中Y表示单键或连接基团；环Z表示可选取的芳基团或杂环芳基团等；R2到R4、P1和Q表示卤素原子、氰基或类似物。
• Amine organocatalysts for highly <i>ortho</i>-selective chlorination of anilines with sulfuryl chloride
  作者：Xinzhe Wang、Zhihuang Chen、Qingqing Liu、Wenqing Lin、Xiaodong Xiong

  DOI：10.1039/d2cc05320a

  日期：——

  A metal catalyst free approach for regioselective ortho-chlorination of anilines has been developed using a secondary amine as the organocatalyst and sulfuryl chloride as the halogen source under mild conditions. A wide range of substrates were compatible with this catalytic system. In addition, this catalytic protocol has been applied to the efficient synthesis of bioactive compounds and modification

  使用仲胺作为有机催化剂和硫酰氯作为卤素源，在温和条件下开发了一种用于苯胺区域选择性邻氯化的无金属催化剂方法。多种底物与该催化系统相容。此外，该催化方案已应用于生物活性化合物的高效合成和药物衍生物的修饰。进一步的研究表明阴离子三氯化物是邻位选择性的原因。